# A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

> **NCT02314117** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 645 (actual)

## Conditions studied

- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Placebo
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT02314117
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-20
- **Primary completion:** 2017-01-17
- **Final completion:** 2020-08-14
- **Target enrollment:** 645 (ACTUAL)
- **Last updated:** 2021-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314117, "A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02314117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*